Use of Darvadstrocel (Allogenic Stem Cell Therapy) for Crohn's Fistulas in Real Clinical Practice: The National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn's Fistula (the PRIME Study).

BACKGROUND: Perianal fistulas may affect 15% to 50% of patients with Crohn's disease. Treatment is complex, requiring a multidisciplinary approach. Darvadstrocel (allogenic mesenchymal cells obtained from lipoaspirates) was approved in 2018 by the European and Spanish Agencies of Medicines and Medical Products as a treatment for fistulas in Crohn's disease. Recent guidelines from the European Crohn's and Colitis Organisation and Spanish Working Group on Crohn's Disease and Ulcerative Colitis state that darvadstrocel is effective with a favorable safety profile and a strong level of evidence (n = 2). OBJECTIVE: Presenting real-world effectiveness data for darvadstrocel in a Spanish population. DESIGN: Observational retrospective cohort study with prospective data gathering. SETTINGS: The study was conducted at 14 institutions in Spain. PATIENTS: From November 2019 to April 2022, all patients (n = 73) treated with darvadstrocel in these institutions were included, fulfilling the following criteria: 1) complex fistula/s in a patient with Crohn's disease; 2) failure of conventional and antitumor necrosis factor treatment; and 3) the absence of collections of >2 cm confirmed by pelvic MRI at the time of surgery. INTERVENTIONS: Darvadstrocel treatment. MAIN OUTCOME MEASURES: Clinical response (closure of 50% or more of external openings), complete clinical closure (100% of external openings), and radiological closure (no fluid collection >2 cm, edema, or inflammation) evaluated 6 months after treatment. RESULTS: Clinical response was observed in 63 patients (86.3%), complete clinical closure in 50 patients (68.5%), and radiological closure in 45 patients (69.2%). Combined clinical and radiological response was observed in 41 patients (63.1%). Not all clinically healed patients had radiological closure, and vice versa. No serious adverse events were reported. LIMITATIONS: Retrospective nature of the study. CONCLUSIONS: Study results were consistent with those reported in previous clinical trials, real-world efficacy findings from the INSPIRE study (assessing darvadstrocel effectiveness in Europe, Israel, Switzerland, United Kingdom, and Japan), and previously published literature. Darvadstrocel was effective and demonstrated a favorable safety profile when used in normal clinical practice for the treatment of fistulas in Crohn's disease. See Video Abstract . USO DE DARVADSTROCEL TERAPIA CON CLULAS MADRE ALOGNICAS PARA FSTULA EN ENFERMEDAD DE CROHN EN LA PRCTICA CLNICA REAL EL PROYECTO NACIONAL PARA IMPLEMENTAR DE CLULAS MADRE MESENQUIMALES PARA EL TRATAMIENTO DE LA FSTULA DE CROHN PERIANAL EL ESTUDIO PRIME: ANTECEDENTES:Las fístulas perianales pueden afectar entre el 15 y el 50% de los pacientes con enfermedad de Crohn. El tratamiento es complejo y requiere un enfoque multidisciplinario. El darvadstrocel (células mesenquimales alogénicas obtenidas a partir de lipoaspirados) fue aprobado en 2018 por las Agencias Europea y Española de Medicamentos y Productos Sanitarios como tratamiento de las fístulas en la EC. Las recientes directrices de la Organización Europea de Crohn y Colitis y del Grupo de Trabajo Español sobre la Enfermedad de Crohn y Colitis Ulcerosa afirman que darvadstrocel es eficaz con un perfil de seguridad favorable y un sólido nivel de evidencia (2).OBJETIVO:Presentar datos de eficacia real de darvadstrocel en población española.DISEÑO:Estudio de cohorte retrospectivo observacional con recopilación prospectiva de datos.ESCENARIO:14 instituciones.PACIENTES:Desde noviembre de 2019 hasta abril de 2022, se incluyeron todos los pacientes (73) tratados con darvadstrocel en estas instituciones, que cumplieron los siguientes criterios: 1) fístula/s compleja/s en un paciente con enfermedad de Crohn; 2) fracaso del tratamiento convencional y anti factor de necrosis tumoral; 3) ausencia de colecciones > 2 cm confirmada por resonancia magnética pélvica en el momento de la cirugía.INTERVENCIONES:Tratamiento con Darvadstrocel.PRINCIPALES MEDIDAS DE RESULTADO:Respuesta clínica (cierre de ≥50% de las aberturas externas), cierre clínico completo (100% de las aberturas externas) y cierre radiológico (sin acumulación de líquido >2 cm, sin edema ni inflamación) evaluados 6 meses después del tratamiento.RESULTADOS:Se observó respuesta clínica en 63 pacientes (86.3%), cierre clínico completo en 50 pacientes (68.5%) y cierre radiológico en 45 pacientes (69.2%). Se observó respuesta clínica y radiológica combinada en 41 pacientes (63.1%). No todos los pacientes clínicamente curados tuvieron cierre radiológico y viceversa. No hubo eventos adversos graves reportados.LIMITACIONES:Estudio retrospectivoCONCLUSIONES:Los resultados del estudio fueron consistentes con los informados en ensayos clínicos anteriores, los hallazgos de eficacia en el mundo real del estudio INSPIRE (que evalúa la efectividad de darvadstrocel en Europa, Israel, Suiza, el Reino Unido y Japón) y la literatura publicada anteriormente. Darvadstrocel fue eficaz y demostró un perfil de seguridad favorable cuando se utiliza en la práctica clínica habitual para el tratamiento de fístulas en la enfermedad de Crohn. (Traducción-Dr. Jorge Silva Velazco ).

[Presacral tumors. Analysis of 20 surgically treated patients]. / Tumores presacros. Análisis de nuestra experiencia en 20 casos tratados quirúrgicamente.

INTRODUCTION: Presacral tumors are a rare and little known pathology. We present our experience in its surgical treatment. METHODS: Analysis of a series (1995-2008). RESULTS: 20 patients (14 women and 6 men), average age 46 (29-71) years. Patients with benign tumors were younger (43.5+/-10.2) years that those who had malignant tumors (62+/-10.7; p = 0.002). The median duration of symptoms was 1 year (2 month-50 years). The first symptom was suppuration, palpable mass or constipation in 10 cases or constipation, abdominal pain in 4, back pain in 4 and a casual finding in 3. The surgical approach was perineal in 9 (45%), abdominal in 8 (40%) and combined in 3 (15%) cases. Fifteen (75%) tumors were benign, with teratomas being the most frequent (5 cases). Another 5 were malignant: 2 chordomas, 1 malignant cystic teratoma, 1 malignant mucinous cystadenocarcinoma and 1 lymphoma. Mean postoperative stay was 6.6+/-5 days. There were post-surgical complications in 5 (20%) patients. After an average follow-up of 3.5+/-4 years, 2 patients died (malignant teratoma and cystadenocarcinoma, respectively) due to morbidity and to a non-resectable recurrence, and a benign schwannoma has recurred, the rest being free of disease. CONCLUSIONS: Surgical treatment by a group of surgeons experienced in perineal and pelvic surgery can obtain good results with few complications, with the exception of some malignant tumors, depending on the infiltration of adjacent structures and their histological type.

Polimorfismos de genes de citocinas na pré-eclâmpsia / Polymorphisms of genes of cytokines in preeclampsia

A pré-eclâmpsia é uma forma de hipertensão exclusiva da gravidez, sendo uma das principais causas de morbimortalidade materna e perinatal em todo o mundo. Diversas evidências mostram que mecanismos imunológicos estão envolvidos em sua fisiopatologia. Neste contexto, a participação das citocinas parece exercer papel importante na ativação do processo inflamatório verificado na doença. Estes fatores estão presentes em todo o processo reprodutivo exercendo papéis tanto de ativação como de inibição de respostas celulares. A identificação dos genes que codificam a produção de diferentes citocinas e a possibilidade de ocorrência de polimorfismo destes genes, modulando eventualmente expressão clínica com padrões diferenciados, trouxe novas perspectivas para avaliar a participação destes mediadores na pré-eclâmpsia. Essa atualização descreve as principais citocinas relacionadas com a gestação e as pesquisas relacionadas aos polimorfismos de genes que codificam IL-10, IL-6, IFN-y, TGF-b e TNF-a na pré-eclâmpsia.

The pre-eclampsia is an exclusive form of hypertension in pregnancy, one of the major causes of fetal and maternal morbidity and mortality throughout the world. Several evidences show that immune mechanisms are involved in its pathogenesis. In this context, the participation of the cytokines seems to play an important role in the activation of the inflammatory process observed in the disease. These factors are present throughout the reproductive process playing a role in the activation as well as in the inhibition of cell answers. The genes identification that codifies the production of different cytokines and the possibility of occurrence of polymorphisms of these genes, modulating eventually clinical expression with differentiated patterns, brought new perspectives to evaluate the participation of these mediators in the preeclampsia. This updating describes the main cytokines related to the gestation and the researches related to the polymorphisms of genes that codify IL-10, IL-6, IFN-y, TGF-b e TNF-a in the pre-eclampsia.

Bcl-2 and Bax expressions in pre-term, term and post-term placentas.

PROBLEM: Placental apoptosis-associated protein imbalance might contribute to the pathogenesis of pre- and post-term birth. Therefore, we evaluated the expression and distribution of pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) molecules in term, pre-term and post-term placentas. METHOD OF STUDY: Placental samples were collected from women with term (n = 25), pre-term (n = 7) and post-term (n = 10) deliveries. The expression of Bcl-2 and Bax was assessed by immunochemistry on paraffin-embedded placental specimens. RESULTS: The pattern of immunostaining for Bcl-2 and Bax was the same in all samples, but not the intensity. The Bax/Bcl-2 ratio was higher in both pre-term and post-term placental samples compared with term placentas as a result of intense reactivity for the pro-apoptotic factor, Bax in pre-term and post-term placentas and, for Bcl-2 decrease in pre-term placentas. CONCLUSION: These findings suggest that different unbalance mechanisms in placental apoptotic-associated protein expressions may be involved in the physiopathology of pre-term and post-term births.

Giant dedifferentiated retroperitoneal liposarcoma.

Liposarcoma tumors only represent 0.1% of all cancers, but they are the more common of retroperitoneal sarcomas. It has a great tendency for local recurrence, mainly the dedifferentiated variety, but its complete resection can provide a 5-year survival of 70%. In this report, we present a case of a giant dedifferentiated retroperitoneal liposarcoma that did not affect any neighboring organ and that was successfully treated by means of complete surgical resection.